Tyra Biosciences Finalizes $400M Underwritten Offering at $22.03/Share
TYRA has more than doubled off its 52-week low of $11.82 on elevated volume (2.4× avg).
Summary
Tyra Biosciences priced a $400M underwritten offering of common stock and pre-funded warrants at $22.03/share, raising ~$373.9M net to fund its dabogratinib development strategy across three indications.
Key Events · Financing and Capital Events · TYRA
-
$400M Underwritten Offering Priced
9,079,000 common shares and 9,078,529 pre-funded warrants sold at $22.03 per share/warrant, generating gross proceeds of $400.0M.
-
Net Proceeds of $373.9M
After $24.0M in underwriting discounts (6% of gross) and $2.1M in estimated expenses, Tyra receives approximately $373.9M to fund the dabogratinib 3x3 strategy in LG-UTUC, IR NMIBC, and achondroplasia.
-
Immediate Dilution of $11.45/Share
New investors pay $22.03 vs. as-adjusted net tangible book value of $10.58 per share, representing immediate dilution of $11.45 per share based on June 30, 2026 financials.
-
60-Day Insider Lock-Up
Executive officers and directors are subject to a 60-day lock-up period; ATM sales under the existing $250M Sales Agreement are paused for 30 days.
Analysis · TYRA · Life Sciences
Tyra Biosciences finalized a $400 million underwritten offering of 9,079,000 common shares and 9,078,529 pre-funded warrants at $22.03 per share, with net proceeds of approximately $373.9 million. The offering was priced on September 14, 2026, just one day after the company filed a universal shelf registration and five days after reporting positive Phase 2 SURF302 data for oral dabogratinib in bladder cancer. The deal adds roughly 18.2 million shares (including pre-funded warrants) to the 59.7 million outstanding as of June 30, 2026 — a substantial capital raise that funds the 'dabogratinib 3x3' development strategy across three indications. Underwriting fees of $24 million (6% of gross proceeds) are standard for a biotech follow-on of this size. The 60-day lock-up on insiders and 30-day ATM pause signal coordinated capital planning, not distress. Existing shareholders face immediate dilution of $11.45 per share based on net tangible book value, but the raise extends cash runway well beyond the previously disclosed H2 2028 horizon.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TYRA was trading at $25.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $11.82 to $40.65. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.